A model-based strategy was used to inform the early clinical development of anacetrapib, a novel cholesteryl ester transfer protein inhibitor under development for the treatment of hyperlipidemia. The objectives of this model-based approach were to enable bridging variable pharmacokinetic effects, differences among formulations used in development, and to identify an appropriate dose for the phase III confirmatory program.
2011 年 06 月 1 日
Author(s): Rajesh Krishna, Arthur Bergman, Michelle Green, Marissa Dockendorf, John Wagner, Kevin Dykstra
Year: 2011 年 06 月 1 日